Trinity Capital Provides $130MM in Growth Capital to Candel Therapeutics
Trinity Capital, an alternative asset manager, committed $130 million in growth capital to Candel Therapeutics, a clinical-stage biopharmaceutical company focused...
Read moreDetails




